<DOC>
	<DOC>NCT01011868</DOC>
	<brief_summary>The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.</brief_summary>
	<brief_title>Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criteria: 1. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation 2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea. 3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of &gt;7.0% and &lt; or = 10% at Visit 1 (screening) 4. Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study) 5. Age &gt; or =18 years at Visit 1 (screening) 6. BMI &lt; or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening) Exclusion criteria: 1. Patients with poorly controlled hyperglycemia 2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy 3. MI, stroke, or TIA within 3 months prior to obtaining informed consent 4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias 6. Treatment with other antidiabetics, antiobesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Premenopausal women on insufficient birth control 8. Alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>